TT Electronics plc (LON:TTG) has noted the recent media coverage in relation to trials of Virolens®, a non-clinical COVID-19 screening device, at Heathrow airport.
TT has been working with iAbra, the creator of Virolens®, and its partners University of Bristol, Dell and Intel, to design, develop and test the prototype Virolens® screening device and to specify and design the manufacturing processes.
TT Electronics has also been appointed exclusive manufacturing partner for the commercial launch of Virolens®. Revenues from Virolens® are dependent on iAbra’s end customers converting expressions of interest into firm orders, and subject to Virolens® meeting further regulatory authority requirements.
